Ismail Jatoi, MD, PhD, FACS Dale H. Dorn Chair in Surgery Professor and Chief, Division of Surgical Oncology University of Texas Health Science Center.

Slides:

Advertisements

Similar presentations

Breast Cancer Patient Issues in Family Practice: An Interactive Session.

Advertisements

Progress Against Breast Cancer

Mammary ductal carcinoma

Baptist Health System General Surgery Residency Program

Oncotype DX® Breast Cancer Assay Clinical Data Review

So you have Breast Cancer: NOW WHAT??? Barbara A. Ward, MD Medical Director The Breast Center at Greenwich Hospital.

Kevin S. Hughes, MD, FACS Co-Director, Avon Comprehensive Breast Evaluation Center Massachusetts General Hospital Associate Professor of Surgery Harvard.

Carolina Breast Cancer Study: Breast cancer subtypes and race Robert Millikan University of North Carolina Chapel Hill, NC.

The Call (a brief tour of breast cancer) Family Medicine Review Course 2011 Christian Cable, MD, FACP.

Julie R. Gralow, M.D. Director, Breast Medical Oncology, Seattle Cancer Care Alliance Professor, Medical Oncology, University of Washington School of Medicine.

Breast Cancer Research in the Developing World Dr. Steven Narod Canada Research Chair in Breast Cancer Boston – November 2009.

Breast Cancer 101 Barbara Lee Bass, MD, FACS Professor of Surgery

Breast Cancer Prevention & Early Detection

Personalized Breast Cancer Care Sunil Patel, MD Medical Oncology and Hematology Collom and Carney Clinic.

Geonomics in Breast Cancer Decoding Human Genome Luis Barreras, M.D., FACP.

Local Management of Invasive Breast Cancer

Breast Cancer Shannan McQuade & Ashley Haman. History of Breast Cancer Ancient Egyptians discovered Breast Cancer –Over 3,500 years ago Hippocrates discovered.

Breast Cancer: Follow up and Management of recurrence Carol Marquez, M.D. Associate Professor Department of Radiation Medicine OHSU.

BIOLOGICAL PRINCIPLES OF BREAST CANCER TREAMENT Benjamin O. Anderson, M.D. Director, Breast Health Clinic Professor of Surgery and Global Health, University.

By Rachel, Xiao Xia, Helen. Introduction Definition Symptoms Causes Prevention Treatment Prognosis Statistics Conclusion.

The All Breast Cancer Report was published in October breastscreen/research.html#breast- cancer-report.

Ductal Carcinoma in situ

Breast Cancer - the Evidence for Current Management

Breast conservation in Locally advanced breast cancer Department of Endocrine Surgery College of Medicine Amrita Institute of Medical Sciences Kochi, Kerala.

CELLULAR BIOLOGY IN BREAST CANCER JESSE ELLMAN MD SEPT 2010 CLINICAL ASSISTANT PROFESSOR DEPT OB GYN AND WOMENS HEALTH WE MAY BE ENTERING A NEW PHASE.

Breast Cancer Clinical Cases Daniel A. Nikcevich, MD, PhD SMDC Cancer Center April 20, 2009.

BREAST CANCER GROUP 6 :  Nuraini Ikqtiarzune Haryono( )  Tri Wahyu Ningsih ( )  Rani Yuswandaru ( )  Anita Rheza Fitriana Putri( )

2 years later, she noticed multiple cm

Wildiers H, et al. Lancet Oncol. 2007;8:1101. Breast Cancer in Elderly (>65 Years) Recommendations of the International Society of Geriatric Oncology Surgical.

Suggested guidelines for appropriate patient selection for patients undergoing Accelerated Partial Breast Irradiation at DMC. Tonya Echols Cole, MD.

 Determining the Nature of a Breast Abnormality  It is a procedure that may be used to determine whether a lump is a cyst (sac containing fluid) or a.

Breast Cancer Management. How treatment is planned The main treatments for breast cancer are Surgery Radiotherapy Hormone therapy Chemotherapy Biological.

ER and PR Test Estrogen and Progesterone receptor status tests will show whether or not one or both of these hormones fuel the tumor Cancer that is hormone-sensitive.

2014 Cancer Program Performance Outcomes. Introduction Saint Agnes Medical Center has proudly maintained a American College of Surgeons’ Commission on.

Breast Cancer By: Christen Scott.

TREATMENT Mastectomy -traditionally, treatment of breast ca has been surgical -19 century, surgical treatment : local excision ~ total mastectomy : radical.

NYU Medical Grand Rounds Clinical Vignette Denise Pate MD, PGY-2 January 27, 2010 U NITED S TATES D EPARTMENT OF V ETERANS A FFAIRS.

San Antonio Breast Cancer Symposium 2012 Helen K. Chew, MD, FACP Professor of Medicine.

 Among all cancers, breast cancer has been the 2 nd leading cause of death in women (right behind lung cancer)  Causes about 40,000 deaths annually.

Neoadjuvant SystemicTreatment Strategies for Breast Cancer Donald W. Northfelt, MD, FACP Professor of Medicine Mayo Clinic College of Medicine Associate.

“Big Data, Better Treatment”: The work of the Early Breast Cancer Trialists’ Collaborative Group Rory Collins BHF Professor of Medicine & Epidemiology.

Breast Cancer. Breast cancer is a disease in which malignant cells form in the tissues of the breast – “National Breast Cancer Foundation” The American.

BREAST CANCER Oncology

Breast cancer. Etiology 1. Increased exposure to estrogens: A)Estradiol-early menarche ( 55) B)Estrone-overweight women C)Xeno-estrogens (contraceptives-increase.

Quality Assurance Report TTUHSC Breast Center of Excellence January 1, 2009 – December 31, 2009.

2015 Cancer Program Performance Outcomes. Introduction Saint Agnes Medical Center has proudly maintained a American College of Surgeons’ Commission on.

Quality Assurance Report TTUHSC Breast Center of Excellence January 1, 2010 – December 31, 2010 Compiled by Lynn Day, RN BSN CCM CCRP.

Multi Disciplinary Cancer Management –Breast Cancer Dr Masalu N. MD Medical Oncologist.

Annals of Oncology 24: 2206–2223, 2013 R3 조영학

Tumor Marker Phenotype Concordance in Second Primary Breast Cancer Monica Brown, MPH, PhD California Cancer Registry Mary Paré, RN, BS Sutter Cancer Center,

By: Anthony, Sophia, Jessica, Terrance, and Sierra.

Kevin S.Hughes, MD, FACS Co-Director, Avon Comprehensive Breast Evaluation Center Massachusetts General Hospital Harvard Medical School Date 06/01/2007.

Breast Cancer Treatment. Treatment 2 aspects 1. Treatment of the breast itself: “Local Treatment” 2. Treatment of the whole body = “Systemic treatment”

BREAST CANCER Anterpreet Neki, MD , MS

Biology and Treatment of Breast Cancer

BREAST CANCER 한림대 강동성심병원 혈액종양내과 이정애 1.

Challenges for the treatment of breast cancer

Case 3 Jane McNicholas Consultant Oncoplastic Breast Surgeon

Number of brain metastasis

Figure 1. Correlation between estrogen receptor (ER), progesterone receptor (PR), and Ki-67 expression in primary breast tumors and synchronous axillary.

Ari Brooks, MD Cancer Surgeon, Big Data End User

Breast Cancer Protocol

Surgical Management of the Breast in Breast Cancer

Case scenario- Breast Lump

Breast Cancer Anne Kelly RN,MS,NP-C AOCNP October 25,2017

Case scenario- Breast Lump

Thanh Nhan Hospital MALE BREAST CANCER: CASE REPORT

Weight Gain and its Correlates among Breast Cancer Survivors

So you have been diagnosed with breast cancer! What's next?

Treatment Overview: The Multidisciplinary Team

Presentation transcript:

Ismail Jatoi, MD, PhD, FACS Dale H. Dorn Chair in Surgery Professor and Chief, Division of Surgical Oncology University of Texas Health Science Center San Antonio, Texas

 Surgery  Radiotherapy  Systemic Therapy (Chemotherapy, Endocrine Therapy, Herceptin)

Virchow Halsted Surgical Treatment of Breast Cancer

 Lumpectomy (Partial Mastectomy, Segmentectomy, Quadrantectomy, Wide Local Excision, Tylectomy, Breast Conserving Surgery) + Removal of Lymph Nodes  Mastectomy + Removal of Lymph Nodes  Mastectomy + Removal of Lymph Nodes + Contralateral Prophylactic Mastectomy

 Generally required after lumpectomy (except for women over age 70 with tumors <2cm, node-negative, ER+, and agree to take endocrine therapy)  Generally not required after mastectomy (except for patients with tumors >5cm or more than 3 positive nodes)

 Pregnancy  Previous Radiotherapy  Collagen Vascular Disease  Large Tumor Size in Relation to Breast Size  Multi-centric Disease  Mutation Carriers (BRCA 1, BRCA 2, etc)

 Estrogen Receptor (ER status)  Progesterone Receptor (PR status)  HER-2 status  Tumor Size  Nodal Status

 ER+/PR+ - Endocrine Therapy (Tamoxifen or Aromatase Inhibitors)  HER Herceptin with Chemotherapy  ER-/PR-/HER-2- (Triple Negative)

 Can Not Treat with Endocrine Therapy (Tamoxifen or Aromatase Inhibitors) or Herceptin  Only Chemotherapy is Beneficial  More Common among BRCA 1 mutation carriers  More Research Needed in Triple Negative Breast Cancers to Improve Outcomes

 Surgical Treatment of Triple Negative Breast Cancers is the Same as for all Breast Cancers  Radiotherapy for Triple Negative Breast Cancers is the Same as for all Breast Cancers  Drug Treatments for Triple Negative Breast Cancers Differ (Endocrine Therapy and Herceptin is not effective for Triple- Negatives, so chemotherapy alone is often used)  More Research Required to Improve Treatment for Triple Negative Breast Cancer